Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Granulomatous infections due to tumor necrosis factor blockade: correction.

Literature DB >> 15486857

Granulomatous infections due to tumor necrosis factor blockade: correction.

Robert S Wallis, Michael Broder, John Wong, David Beenhouwer.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2004 PMID： 15486857 DOI： 10.1086/424455

Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079

Keyword Cloud
Cited

× No keyword cloud information.

47 in total

Review 1. Averting inflammation by targeting the cytokine environment.

Authors: Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal: Nat Rev Drug Discov Date: 2010-09 Impact factor: 84.694

2. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal: Ann Rheum Dis Date: 2006-11 Impact factor: 19.103

Review 3. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal: Ann Rheum Dis Date: 2007-11 Impact factor: 19.103

4. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Authors: F Tubach; D Salmon; P Ravaud; Y Allanore; P Goupille; M Bréban; B Pallot-Prades; S Pouplin; A Sacchi; R M Chichemanian; S Bretagne; D Emilie; M Lemann; O Lortholary; O Lorthololary; X Mariette
Journal: Arthritis Rheum Date: 2009-07

Review 5. [Rheumatology].

Authors: H U Scherer; G R Burmester
Journal: Internist (Berl) Date: 2005-08 Impact factor: 0.743

10. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Authors: W G Dixon; K L Hyrich; K D Watson; M Lunt; J Galloway; A Ustianowski; D P M Symmons
Journal: Ann Rheum Dis Date: 2009-10-22 Impact factor: 19.103

Granulomatous infections due to tumor necrosis factor blockade: correction.

Review 1. Averting inflammation by targeting the cytokine environment.

2. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Review 3. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

4. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Review 5. [Rheumatology].

Review 6. Advancing host-directed therapy for tuberculosis.

Review 7. Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

8. Preventing tuberculosis in children receiving anti-TNF treatment.

Review 9. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.

10. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).